Ipsen S.A. (IPN.PA)
| Previous Close | 114.10 |
| Open | 115.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 114.40 - 116.40 |
| 52 Week Range | 99.70 - 130.70 |
| Volume | |
| Avg. Volume | 76,731 |
| Market Cap | 9.519B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 15.53 |
| EPS (TTM) | 7.41 |
| Earnings Date | Jul 24, 2024 |
| Forward Dividend & Yield | 1.20 (1.05%) |
| Ex-Dividend Date | May 30, 2024 |
| 1y Target Est | 125.00 |
GlobeNewswireIpsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executive Leadership Team (ELT) and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “We are thrilled to welcome Keira to Ipsen as our new President of North America as she brings extensive experience in the life sciences industry
- GlobeNewswire
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER1Growth platforms2509.7452.012.8%16.2%New medicines345.514.3n/an/aSomatuline®257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5%Total Sales822.4741.910.9%13.3% Highlights Total-sales growth of 13.3% at CER1, or 10.9% as reported, driven by the 16.2%1 increase in sales of the growth platforms2
- GlobeNewswire
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disordersThis promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape1 PARIS, FR
